Loading…
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $81M | $-89M | $-114M | $-51M | 1971.4% | 144.6% | - |
| 2024 | $33M | $-122M | $-148M | $-109M | -217.9% | 137.4% | - |
| 2023 | $14M | $-57M | $-84M | $-126M | -60.8% | -12.0% | - |
| 2022 | $16M | $-116M | $-130M | $-118M | -110.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 15.92 | 14.02 | 33.28 | 81.39 |
| Cost Of Revenue | 0 | 0 | 23.79 | 4.84 |
| Gross Profit | 0 | 14.02 | 9.49 | 76.55 |
| Operating Expense | 132.28 | 151.08 | 173.70 | 182.52 |
| Operating Income | -116.36 | -137.06 | -164.21 | -105.97 |
| EBITDA | -116.07 | -57.06 | -121.84 | -89.40 |
| EBIT | -124.67 | -70.78 | -134.52 | -102 |
| Pretax Income | -129.62 | -84.03 | -147.79 | -114.20 |
| Net Income | -129.62 | -84.03 | -147.79 | -114.20 |
| Net Income Common Stockholders | -129.62 | -84.03 | -147.79 | -114.20 |
| Total Expenses | 132.28 | 151.08 | 197.49 | 187.36 |
| Interest Expense | 4.95 | 13.24 | 13.27 | 12.20 |
| Interest Income | 0.78 | 2.27 | 4.14 | 1.82 |
| Research And Development | 85.72 | 103.78 | 119.48 | 129.62 |
| Selling General And Administration | 46.55 | 47.29 | 54.22 | 52.90 |
| Normalized EBITDA | -106.97 | -120.57 | -147.39 | -91.54 |
| Normalized Income | -120.52 | -147.53 | -173.34 | -116.35 |
| Basic EPS | -2.87 | -1.49 | -2.12 | -1.42 |
| Diluted EPS | -2.87 | -1.49 | -2.12 | -1.42 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | -9.09 | 63.51 | 25.55 | 2.15 |
| Total Unusual Items Excluding Goodwill | -9.09 | 63.51 | 25.55 | 2.15 |
| Net Income From Continuing Operation Net Minority Interest | -129.62 | -84.03 | -147.79 | -114.20 |
| Reconciled Depreciation | 8.60 | 13.72 | 12.68 | 12.61 |
| Reconciled Cost Of Revenue | 0 | 0 | 23.79 | 4.84 |
| Net Interest Income | -4.17 | -10.97 | -9.13 | -10.38 |
| Net Income From Continuing And Discontinued Operation | -129.62 | -84.03 | -147.79 | -114.20 |
| Total Operating Income As Reported | -116.36 | -137.06 | -164.21 | -105.97 |
| Diluted Average Shares | 45.18 | 56.49 | 69.82 | 80.43 |
| Basic Average Shares | 45.18 | 56.49 | 69.82 | 80.43 |
| Diluted NI Availto Com Stockholders | -129.62 | -84.03 | -147.79 | -114.20 |
| Net Income Including Noncontrolling Interests | -129.62 | -84.03 | -147.79 | -114.20 |
| Net Income Continuous Operations | -129.62 | -84.03 | -147.79 | -114.20 |
| Other Income Expense | -9.09 | 64.01 | 25.55 | 2.15 |
| Other Non Operating Income Expenses | 0.36 | 0.50 | 0 | 0 |
| Special Income Charges | 0 | 54.21 | 28.43 | 0 |
| Gain On Sale Of Ppe | 0 | 54.21 | 28.43 | 0 |
| Gain On Sale Of Security | -9.09 | 9.30 | -2.89 | 2.15 |
| Net Non Operating Interest Income Expense | -4.17 | -10.97 | -9.13 | -10.38 |
| Interest Expense Non Operating | 4.95 | 13.24 | 13.27 | 12.20 |
| Interest Income Non Operating | 0.78 | 2.27 | 4.14 | 1.82 |
| General And Administrative Expense | 46.55 | 47.29 | 54.22 | 52.90 |
| Other Gand A | 46.55 | 47.29 | 54.22 | 52.90 |
| Operating Revenue | 15.92 | 14.02 | 33.28 | 81.39 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| MeiraGTx Holdings plcthis co. | MGTX | $828M | - | -126.06 | 1971.4% | -8.05 |
| Janux Therapeutics, Inc. | JANX | $860M | - | 0.89 | -11.9% | 0.55 |
| EVMN | EVMN | $859M | - | 3.66 | -33.5% | -8.93 |
| Theravance Biopharma, Inc. | TBPH | $859M | 8.09 | 2.87 | 35.7% | -296.42 |
| MannKind Corporation | MNKD | $849M | 137.50 |
| -16.57 |
| -11.5% |
| 19.49 |
| Omada Health, Inc. | OMDA | $841M | - | 3.60 | -5.6% | -94.35 |
| OPKO Health, Inc. | OPK | $838M | - | 0.66 | -17.8% | -7.47 |
| First Tracks Biotherapeutics, Inc. | TRAX | $821M | - | - | -41.8% | - |
| Arbutus Biopharma Corporation | ABUS | $813M | - | 10.38 | -43.7% | -26.98 |
| Peer Median | - | 72.80 | 2.87 | -14.8% | -8.93 | |